A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired ...

Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted therapies that are more effective and tolerable than traditional ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images.

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...